Literature DB >> 29298106

The complications of treating chronic obstructive pulmonary disease in low income countries of sub-Saharan Africa.

Frederik A van Gemert1,2, Bruce J Kirenga1,2,3, Tewodros Haile Gebremariam4, George Nyale5,6, Corina de Jong1, Thys van der Molen1,2.   

Abstract

INTRODUCTION: In most low and middle-income countries, chronic obstructive pulmonary disease (COPD) is on the rise. Areas covered: Unfortunately, COPD is a neglected disease in these countries. Taking sub-Saharan Africa as an example, in rural areas, COPD is even unknown regarding public awareness and public health planning. Programs for the management of COPD are poorly developed, and the quality of care is often of a low standard. Inhaled medication is often not available or not affordable. Tobacco smoking is the most common encountered risk factor for COPD. However, in sub-Saharan Africa, household air pollution is another major risk factor for the development of COPD. Communities are also exposed to a variety of other risk factors, such as low birth weight, malnutrition, severe childhood respiratory infections, occupational exposures, outdoor pollution, human-immunodeficiency virus and tuberculosis. All these factors contribute to the high burden of poor respiratory health in sub-Saharan Africa. Expert commentary: A silent growing epidemic of COPD seems to be unravelling. Therefore, prevention and intervention programs must involve all the stakeholders and start as early as possible. More research is needed to describe, define and inform treatment approaches, and natural history of biomass-related COPD.

Entities:  

Keywords:  Biomass fuel use; COPD; chronic respiratory disease; developing countries; household air pollution; low income countries; sub-Saharan Africa

Mesh:

Year:  2018        PMID: 29298106     DOI: 10.1080/17476348.2018.1423964

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN: 1747-6348            Impact factor:   3.772


  4 in total

1.  Stepped treatment algorithm using budesonide-formoterol for chronic respiratory diseases: A single arm interventional study.

Authors:  Wan-Chun Huang; Greg J Fox; Ngoc Yen Pham; Thu Anh Nguyen; Van Giap Vu; Viet Nhung Nguyen; Stephen Jan; Joel Negin; Quy Chau Ngo; Guy B Marks
Journal:  PLoS One       Date:  2022-07-11       Impact factor: 3.752

2.  Availability and affordability of medicines and diagnostic tests recommended for management of asthma and chronic obstructive pulmonary disease in sub-Saharan Africa: a systematic review.

Authors:  Davis Kibirige; Richard E Sanya; Rebecca Nantanda; William Worodria; Bruce Kirenga
Journal:  Allergy Asthma Clin Immunol       Date:  2019-03-07       Impact factor: 3.406

3.  Prevalence of chronic obstructive pulmonary disease (COPD) and its associated factors among adults in Abeshge District, Ethiopia: a cross sectional study.

Authors:  Gashaw Garedew Woldeamanuel; Alemu Basazin Mingude; Teshome Gensa Geta
Journal:  BMC Pulm Med       Date:  2019-10-17       Impact factor: 3.317

4.  Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis.

Authors:  Davies Adeloye; Peige Song; Yajie Zhu; Harry Campbell; Aziz Sheikh; Igor Rudan
Journal:  Lancet Respir Med       Date:  2022-03-10       Impact factor: 102.642

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.